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TET2 encodes an enzyme that hydroxylates methylcytosine and is frequently targeted by loss-of-function
mutations in myelodysplasia, myeloproliferative disorders, and acute myeloid leukemia. In this issue of
Cancer Cell, two studies show that inactivation of Tet2 enhances hematopoietic stem cell self renewal and
promotes the development of myeloproliferative disorders.TET2 (tet oncogene family member 2, or
Ten-Eleven Translocation 2) is a member
of a family of genes with important roles
in epigenetic programming, embryonic
stemcellmaintenance, and early develop-
ment (Ito et al., 2010). Apotential role in the
pathogenesis of hematologic neoplasms
was first recognized with the identification
of rearrangements of TET1 in acute
leukemia (Lorsbachet al., 2003). Recently,
a plethora of reports have identified a high
frequency of loss-of-function mutations
of the TET2 gene in hematologic malig-
nancies, including myelodysplastic syn-
drome, myeloproliferative neoplasms
(MPN), and de novo and secondary acute
myeloid leukemia (AML). Notably, up to
50%of chronicmyelomonocytic leukemia
(CMML), a mixed myelodysplastic and
myeloproliferative condition with a
propensity to progress to AML, harbor
TET2 mutations. Moreover, CMML with
TET2 alterations appear to harbor fewer
concomitant copy number alterations
and mutations compared to TET2 wild-
type CMML (Abdel-Wahab et al., 2009;
Jankowska et al., 2009). Consequently,
there is intense interest in elucidating the
role of TET2 in hematopoiesis, epigenetic
regulation, and leukemogenesis.
A key role of the TET family of enzymes
is to convert 5-methyl-cytosine (mC) to
5-hydroxymethyl-cytosine (hmC) (Fig-
ure 1) (Tahiliani et al., 2009). The role of
5hmC is incompletely understood;
however, recent genome-wide analyses
in mouse embryonic stem cells have
shown hmC to be enriched in actively
transcribed genes and in the promoter
regions of Polycomb-repressed develop-
mental regulators (Wu et al., 2011). The
TET2 mutations in hematologic tumors
occur throughout the gene and include
missense, nonsense, and frameshift
mutations. Missense mutations are com-monly found in the functional domains of
TET2, including the cysteine-rich and
catalytic double-stranded b helix do-
mains, suggesting that the mutations
result in loss of TET2 function. TET2muta-
tions are associated with low hmC levels
and global hypomethylation (Ko et al.,
2010). Moreover, mutations of TET2 and
the isocitrate dehydrogenase genes
IDH1/IHD2 are mutually exclusive in
AML, and the metabolic product of the
neomorphic IDH1/2 mutant proteins,
2-hydroxyglutarate, inhibits the catalytic
activity of TET2 (Figure 1) (Figueroa
et al., 2010; Xu et al., 2011). TET2 muta-
tions may be acquired prior to JAK2
mutations in MPNs, but also at the
progression of MPN to AML. The Tet
genes are expressed in early hematopoi-
etic progenitors, with downregulation
during differentiation, and inhibition of
Tet2 expression promotes expansion of
monocyte-macrophage lineage cells
in vitro. Together, these observations
suggest that TET2 has key roles in epige-
netic regulation and hematopoiesis, and
that TET2 mutations are central events
in leukemogenesis. However, these
hypotheses have not been formally tested
in vivo.
Two studies in this issue of Cancer Cell
report murine models of Tet2 inactivation
that establish important roles for Tet2 in
hematopoiesis and the development of
myeloproliferative disease, and show
that lymphoid as well as myeloid malig-
nancies harbor TET2 mutations. Initial
in vitro studies by Moran-Crusio et al.
(2011) showed that short hairpin RNA-
mediated silencing of Tet2 in murine
bone marrow cells resulted in enhanced
replating ability in colony forming assays,
upregulation of the hematopoietic stem,
and progenitor cell marker c-Kit and
a decrease in global hmC levels. TheseCancer Cauthors engineered a mouse model with
conditional Tet2 loss in the hematopoietic
compartment by targeting exon 3, a
commonly mutated exon in human my-
eloid malignancies (Moran-Crusio et al.,
2011). Quivoron et al. (2011) created two
different Tet2 deficient mouse models,
where one had an insertion of a b-galacto-
sidase-neomycin cassette in the Tet2
gene (Tet2LacZ), giving rise to a dysfunc-
tional Tet2-b-galactosidase transcript.
The second was a conditional knockout
of Tet2 that, upon Cre-mediated recombi-
nation, resulted in expression of a trun-
cated Tet2 protein lacking the last 490
amino acids of the carboxy terminus,
including the catalytic domain (Quivoron
et al., 2011).
In the study of Moran-Crusio et al.
(2011), Vav-cre+Tet2/ mice lacked
Tet2 expression in the hematopoietic
lineage, and like shRNA-silenced Tet2
cells, Vav-cre+Tet2/ deficient cells
exhibited serial replating. The Tet2/
cells had upregulated levels of c-Kit
and myeloid progenitor markers (e.g.,
CD34 and FcgR), and a gene expres-
sion profile similar to that of common
myeloid progenitors, indicating that
these cells are c-Kit+ myeloid progenitors.
Tet2 deficiency was shown to result in
progressive perturbations in hematopoi-
esis in vivo in both studies. Tet2 loss
resulted in expansion of the hematopoi-
etic stem cell (HSC) compartment
and granulocyte-macrophage progenitor
population in the marrow, splenomegaly,
and extramedullary hematopoiesis. Quiv-
oron et al. (2011) also observed the
expansion of an aberrant immature
(CD19+B220low) lymphoid population in
Tet2 deficient mice. With age, two out of
the three mouse models (Tet2LacZ and
Vav-cre+Tet2/) developed a disease
reminiscent of human CMML that wasell 20, July 12, 2011 ª2011 Elsevier Inc. 1
Figure 1. Schematic of the Regulatory Network of
TET2
HSC, hematopoietic stem cell; mC, 5-methyl-cytosine. 2-
Hydroxyglutarate is the metabolic product of mutated,
neomorphic IDH1 and IDH2 proteins.
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and splenomegaly.
TET2 alterations in patients are
most commonly heterozygous,
suggesting that TET2 haploinsuffi-
ciency may be sufficient to result
in hematopoietic progenitor
defects and myeloproliferation.
Accordingly, in vitro and in vivo
experiments using Tet+/ mice
demonstrated that the heterozy-
gous cells behaved in a similar
fashion as Tet2 null cells, with serial
replating potential and expansion
of myeloid lineage cells. Tet+/ cells
also exhibited a competitive advan-
tage over Tet2 wild-type cells in
transplantation assays, although
unsurprisingly this expansion
occurred over a longer time period
than with Tet2/ cells.
The role of TET2 alterations in
lymphoid malignancies has been
less well studied. Several patients
with TET2 mutant myeloid malig-
nancies have been noted to develop
lymphoma, prompting Quivoron
et al. (2011) to sequence TET2 in
a range of mostly mature B andT cell neoplasms. This identified delete-
riousmutations in 2%ofBcell andapprox-
imately 12% of T cell lymphomas, notably
in 30% of angioimmunoblastic T cell
lymphoma, an aggressive neoplasm of
CD4+ T-lymphocytes. Prior TET2 geno-
typing studies in myeloid disorders have
shown that the TET2 mutations are
commonly present in hematopoietic
progenitors, and interestingly, the same
phenomenon was observed in several
patients with lymphoma. One patient that
harbored two TET2 mutations sub-
sequently developedAML,andbothmuta-
tions were also detected in the
AML sample. A second patient with T cell
lymphoma also had two TET2 mutations,
one of which was also detected in
a fraction of HSCs, indicating that
these alterations are commonly acquired
in early hematopoietic progenitors,
irrespective of the lineage of the subse-
quent neoplasm. Further studieswere per-
formed to determine if the TET2mutations
identified in lymphomaswere derived from
early hematopoietic progenitors and iden-2 Cancer Cell 20, July 12, 2011 ª2011 Elsevitified the mutations in progenitor cells with
myeloid differentiation potential.
Together, these data provide important
mechanistic insights into the role of TET2
in normal and malignant hematopoiesis.
These studies show that Tet2 loss results
in expansion of hematopoietic stem and
progenitor cell populations and directly
contributes to myeloproliferation, consis-
tent with a central role of TET2 disruption
by deletion or sequence mutation in the
pathogenesis of lymphoid as well as
myeloid disorders (Figure 1). Moreover,
the mutations in both lineages of malig-
nancy are commonly acquired in early
hematopoietic progenitors of multilineage
potential, indicating that enhanced self
renewal consequent on TET2 inactivation
is an important mechanism of transforma-
tion. Moreover, genomic profiling and
sequencing efforts are implicating an
increasing number of genes with roles in
cytosine and histone modification in a
range of hematologic and solid tumors
including IDH1, IDH2, DNM3TA, and the
polycomb repressive complex 2 geneser Inc.EZH2 and SETD2 and others, indi-
cating that perturbations in epige-
netic programming are key events
in tumorgenesis and that these
epigenetic alterations may be driven
by genetic alterations in the genes
encoding this machinery. Future
work modeling these pathways in
tumorigenesis will be of interest,
and the models described here
provide an important platform to
study these genes and to test the
efficacy of therapeutic agents de-
signed to modulate these epigenetic
alterations.REFERENCES
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